Neuphoria Therapeutics Inc. (NEUP) Financial Ratios
27 years of historical data (1999–2025) · Healthcare · Medical - Pharmaceuticals
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
0.30
↑+102% vs avg
5yr avg: 0.15
30Y Low0.1·High0.1
P/B Ratio
↓
0.24
↓-100% vs avg
5yr avg: 135.34
30Y Low0.4·High78.8
ROE
↑
-1.6%
↓+98% vs avg
5yr avg: -70.6%
30Y Low-144%·High8%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
NEUP Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Neuphoria Therapeutics Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis. On a free-cash-flow basis, the stock trades at 0.3x P/FCF, 102% above the 5-year average of 0.1x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $23M | $12M | $1.4B | $3.2B | $9.5B | — | — | — | — | — | — |
| Enterprise Value | $2M | $-9842557 | $1.4B | $3.2B | $9.4B | — | — | — | — | — | — |
| P/E Ratio → | -18.74 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 1.49 | 0.74 | — | — | 35886.73 | — | — | — | — | — | — |
| P/B Ratio | 0.24 | 0.40 | 78.80 | 220.54 | 241.63 | — | — | — | — | — | — |
| P/FCF | 0.30 | 0.15 | — | — | — | — | — | — | — | — | — |
| P/OCF | 0.30 | 0.15 | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
NEUP EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | -0.63 | — | — | 35800.95 | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | -0.13 | — | — | — | — | — | — | — | — | — |
NEUP Profitability
Margins and return-on-capital ratios measuring operating efficiency
Neuphoria Therapeutics Inc. earns an operating margin of -7.2%. A negative ROE of -1.6% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | — | — | 100.0% | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Margin | -7.2% | -7.2% | — | — | -8095.2% | — | -19319.3% | -401.6% | -771.8% | -261.5% | -415.7% |
| Net Profit Margin | -2.4% | -2.4% | — | — | -8253.7% | — | -15255.2% | -252.8% | -668.3% | -125.6% | -237.8% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -1.6% | -1.6% | -144.3% | -119.6% | -58.1% | -29.4% | -46.3% | -54.5% | -84.6% | -16.5% | -44.1% |
| ROA | -1.0% | -1.0% | -98.6% | -100.1% | -50.8% | -20.3% | -16.0% | -15.9% | -32.8% | -8.0% | -20.9% |
| ROIC | -13.4% | -13.4% | -334.6% | -212.2% | -101.5% | -46.4% | -32.5% | -65.7% | -142.8% | -60.5% | -108.8% |
| ROCE | -3.7% | -3.7% | -129.4% | -109.9% | -52.3% | -31.4% | -27.0% | -32.6% | -46.3% | -19.4% | -43.5% |
NEUP Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $22M exceeds total debt of $226487, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.02 | 0.02 | 0.01 | 0.02 | 0.96 | 0.97 | 1.27 | 0.46 | 0.53 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.74 | -0.71 | -0.53 | -0.58 | -0.58 | 0.60 | 0.18 | -0.20 | -0.60 | -0.55 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | -0.28 | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -1185.93 | -5.38 | -2.35 | -3.19 | -11.75 | -2.16 | -8.15 |
Net cash position: cash ($22M) exceeds total debt ($226487)
NEUP Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Neuphoria Therapeutics Inc.'s current ratio of 3.56x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 4.87x to 3.56x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.56 | 3.56 | 3.45 | 4.87 | 12.46 | 13.10 | 1.01 | 1.82 | 2.70 | 3.92 | 5.10 |
| Quick Ratio | 3.56 | 3.56 | 3.45 | 4.87 | 12.46 | 13.10 | 1.01 | 1.77 | 2.67 | 3.89 | 5.06 |
| Cash Ratio | 3.37 | 3.37 | 3.29 | 4.42 | 10.00 | 12.07 | 0.55 | 1.05 | 1.92 | 3.13 | 4.04 |
| Asset Turnover | — | 0.36 | — | — | 0.01 | — | 0.00 | 0.07 | 0.06 | 0.06 | 0.08 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | 6462.14 | — | 463.78 | 84.63 | 69.30 | 671.71 | 575.11 |
NEUP Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Neuphoria Therapeutics Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | 100.0% | 670.2% | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — |
| Shares Outstanding | — | $2M | $150M | $122M | $113M | $65M | $45M | $43M | $40M | $40M | $38M |
Peer Comparison
Compare NEUP with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 NEUPYou | $23M | -18.7 | — | 0.3 | 100.0% | -7.2% | -1.6% | -13.4% | — |
 ACAD | $4B | 9.4 | 25.7 | 35.2 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 INVA | $2B | 6.8 | 6.8 | 8.5 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 PRAX | $8B | -20.9 | — | — | — | — | -45.8% | -65.0% | — |
 BIIB | $29B | 22.3 | 11.7 | 14.2 | 70.5% | 19.1% | 7.4% | 6.5% | 2.5 |
 ALKS | $7B | 31.5 | 22.9 | 15.6 | 86.7% | 17.2% | 14.7% | 18.9% | 0.2 |
 AXSM | $13B | -68.1 | — | — | 92.6% | -26.5% | -252.1% | -1906.7% | — |
 NRXP | $69M | -3.0 | — | — | 58.8% | -1324.4% | — | — | — |
 SAVA | $64M | -2.5 | — | — | — | — | -17.2% | -634.1% | — |
 CRL | $9B | -63.6 | 12.9 | 17.2 | 30.5% | 12.6% | -4.3% | 6.3% | 3.4 |
 IQV | $28B | 21.4 | 12.4 | 13.9 | 26.3% | 14.0% | 21.4% | 8.7% | 4.7 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.2% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 27 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
NEUP — Frequently Asked Questions
Quick answers to the most common questions about buying NEUP stock.
What is Neuphoria Therapeutics Inc.'s P/E ratio?
Neuphoria Therapeutics Inc.'s current P/E ratio is -18.7x. This places it at the 50th percentile of its historical range.
What is Neuphoria Therapeutics Inc.'s ROE?
Neuphoria Therapeutics Inc.'s return on equity (ROE) is -1.6%. The historical average is -45.4%.
Is NEUP stock overvalued?
Based on historical data, Neuphoria Therapeutics Inc. is trading at a P/E of -18.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Neuphoria Therapeutics Inc.'s profit margins?
Neuphoria Therapeutics Inc. has 100.0% gross margin and -7.2% operating margin.